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Abstract 
Inflammatory bowel disease (IBD) is a chronic and relapsing inflammatory condition 
of the gastrointestinal tract. The two main forms of IBD are Crohn's disease and ulcerative 
colitis. According to the recent concept the disease is caused by a combination of factors, 
including genetics, immune dysregulation, barrier dysfunction and the change in microbial 
flora. Environmental factors, such as changes in diet, antibiotic use, smoking or improved 
domestic hygiene (e.g. eradication of intestinal helminths) probably contribute to the 
development and increased prevalence of IBD. Dysregulation of mucosal immunity in IBD 
causes an overproduction of inflammatory cytokines resulted in uncontrolled intestinal 
inflammation. Based on extensive research over the last decade, besides the conventional 
therapy, there are several novel pathways and specific targets, on which focus new 
therapeutics. New therapeutics aim 1./ to correct genetic susceptibility by stimulating NOD2 
expression, TLR3 signaling or inhibition of TLR4 pathway, 2./ to restore the immune 
dysregulation by inhibition of pro-inflammatory cytokines (TNF-α, IL-6, IL-13, IL-17, IL-18, 
IL-21), Th1 polarisation (IL-2, IL-12, IL-23, IFN-γ), T-cell activation, leukocyte adhesion, as 
well as by immunostimulation (GM-CSF, G-CSF) and anti-inflammatory cytokines (IL-10, 
IL-11, IFN-β-1a), 3./ to restore mucosal barrier function and stimulate mucosal healing by 
different growth factors, such as GH, EGF, KGF, TGF-β, VEGF, 4./ to restore the normal 
bacterial flora by antibiotics, probiotics. However, in spite of these numerous potential 
targets, the true value and clinical significance of most of the new biologics and molecules are 
not clear yet. 
1. Introduction 
Inflammatory bowel disease (IBD), a chronic and relapsing inflammatory condition of 
the gastrointestinal (GI) tract.The two main forms of IBD are Crohn's disease (CD) and 
ulcerative colitis (UC), though other forms are also known, which are also classified as not 
typical IBD (e.g. collagenous colitis, lymphocytic colitis, ischaemic colitis, diversion colitis, 
Behçet's disease, indeterminate colitis). 
The cause of IBD is not exactly known. The recent consensus is that IBDs are initiated 
and perpetuated by an impaired immune response against the gut microbiota in genetically 
susceptible individuals [1, 2] and the disease is caused by a combination of factors, including 
genetics, immune dysregulation, barrier dysfunction, change in microbial flora and 
environmental influences (see reviews [3-7]). 
Though UC and CD share some common clinical symptoms, the two diseases possess 
very distinct features. First of all, the location of the inflammation is different; CD can 
develop at any part of the intestine, though most of the cases are localized at the terminal 
ileum. In contrast, in UC the inflammatory process is restricted to the colon and the rectum. 
Moreover, the pathological changes in CD affect the whole bowel wall and manifested as 
transmural lesions, while in UC the inflammation is restricted to the mucosa (epithelial lining 
of the gut). Also differences in immunological response of intestinal mucosa have been 
described. CD is associated with the activation of types 1 and 17 T-helper (Th) cells in 
response to interleukin (IL)-12, IL-18, IL-23 and transforming growth factor β (TGF-β), and 
activation of these cells results in increased secretion of the pro-inflammatory cytokines IL-2, 
IL-17, interferon (IFN)-γ and TNF-α [8, 9]. In patients with UC the mucosal inflammation of 
the colon is mainly associated with a Th2 cell activation mediated by IL-4, IL-5 and IL-13 
that results in an increased level of IL-13 [10, 11]. However, in both cases T-cells are also 
activated by direct contact with antigens [12]. 
As regards the clinical symptoms, body weight loss and fever more common in CD. 
Ulcerations, granulomas, and bowel fistulas are characteristic for CD, in contrast, UC affects 
the mucosa in a continuous manner. Moreover, smoking was found to be protective against 
UC and might improve its course, but seems to increase the risk of developing CD and 
worsens its course [13]. 
On the other hand, extra-intestinal manifestations (liver problems, arthritis, skin 
manifestations and eye problems) can develop in both CD and UC. Some patients have an 
extra-intestinal manifestation as their first symptom of the disease, while they still have only 
mild gastrointestinal manifestation, or none at all. Anemia is the most prevalent extraintestinal 
complication of both IBDs [14, 15]. 
The chronic inflammation of the gut causes wide-ranging clinical symptoms in both 
forms, like nausea, diarrhea (which is often porridge-like in CD, while mucus-like with blood 
in UC) or constipation [16, 17]. 
UC or CD patients have increased risk for colorectal carcinoma (CRC). Patients with 
UC and Crohn’s ileocolitis have an elevated risk of developing colon cancer, while patients 
with CD and enteritis have an elevated risk of developing small-bowel cancer [18, 19]. The 
cumulative risk for developing colorectal cancer was 8% at 22 years from onset of symptoms 
for Crohn’s colitis and 7% at 20 years from onset of symptoms for UC, as it accounts for one 
in six of all deaths in IBD patients [20]. 
The high incidence and prevalence of IBD (worldwide incidence of UC and CD varies 
between 0.5-24.5 and 0.1-16 individuals per 100.000 inhabitants, respectively) [21], and the 
costs of the long-term and only symptomatic treatment of the patients place a significant 
burden on the healthcare system: the expenses exceed 1.7 billion dollars per year in the 
United States [22], and are in similar range in European countries. 
Although in the last decade our knowledge about the pathomechanism of IBDs greatly 
expanded (which is also clearly demonstrated by the continuously rising number of 
publications in this field), and several important milestones have been achieved, distinction 
between causing events and secondary consequences is still challenging. 
The aim of this review is to shortly summarize the current knowledge and newest 
findings in the pathomechanism of IBD as well as to overview some of the therapeutic targets 
and strategies (convential and novel ones) for the treatment of IBD. 
 
2. Patomechanism 
2.1. Genetic susceptibility 
 
The familial aggregation of IBD has already been observed several decades ago and 
studies conducted on twins also confirmed the importance of hereditary factors in the 
pathogenesis of IBD (especially for CD), though they also highlighted the role of 
environmental trigger factors [23-27]. 
Genome wide association studies (GWASs) performed during recent years provided 
better insight into the genetic background of IBD. They revealed 163 genomic susceptibility 
loci associated with IBD so far, 110 with both disease phenotypes, and further 30 and 23 
associated selectively either with CD or UC, respectively [28, 29]. The considerable overlap 
of susceptibility loci in CD and UC indicates that these two IBD phenotypes share several 
common factors in their pathogenesis. 
Although the exact functional role of several IBD susceptibility genes still remains to be 
established, many of them are associated with host immune functions, including both innate 
and adaptive immunity. 
The first susceptibility gene identified for CD was NOD2/CARD15, which brought the 
role of innate immunity and pattern recognition receptors (PRRs) in the pathogenesis of IBD 
to the fore. As described in the next section, PRRs play an essential role in the host microbial 
interaction by sensing conserved microbial structures (pathogen-associated molecular 
patterns, PAMPs). Binding of PAMPs results in the activation of multiple signaling pathways 
including nuclear factor-κB (NF-κB) and mitogen activated protein kinases (MAPKs), which 
in turn induce the production of inflammatory mediators and also initiate multiple cellular 
processes, including cell proliferation and differentiation [30-32]. NOD2, a member of the 
nucleotide-binding oligomerization domain (NOD)-like receptor (NLR) family, recognizes 
muramyl dipeptide (MDP), a component of peptidoglycan (PGN) in nearly all bacteria [30]. 
The three most common NOD2 mutations, a frame-shift insertion mutation (3020insC) and 
two missense mutations (R702W and G908R) result in impaired recognition of MDP and in 
loss of NF-κB activation in response to lipopolysaccharide (LPS) and PGN [33-36]. Several 
groups confirmed the association of NOD2 with CD, but interestingly, no such connection 
was found in Japanese individuals [37]. This is in line with other findings (see below) 
indicating that genetic determinants can differ significantly between populations. 
In the last 2 decades several other PRR genes have been associated with IBD. A british 
group reported that a complex insertion/deletion polymorphism in NOD1/CARD4 (+32656) 
may contribute to the development of IBD and can result earlier onset and extra-intestinal 
manifestations [38], but other groups could not reproduce these findings in German [39], 
Scottish and Swedish patients [40]. 
Single nucleotide polymorphisms (SNPs) in Toll-like receptor (TLR) TLR1 and TLR2 
genes (R80T and R753Q) were found to increase the risk of pancolitis in UC, but did not 
increase the susceptibility to disease development [41]. 
Several studies have been conducted to identify the role of the TLR4 gene in the 
pathogenesis of IBD, but similarly to NOD2, substantial heterogeneity was found between 
populations. The D299G SNP was associated with IBD in Belgian [42], German [43, 44], 
Greek [45] or Australian [46], but not in Southern Italian [47], Hungarian [48] or New 
Zealand patients [49, 50]. Nevertheless, meta-analyses have provided evidences for an 
association between D299G and IBD [49, 50]. Similar discrepancies were observed with the 
T399I SNP, because significantly increased allele and carrier frequencies for this mutation 
were observed in patients with UC in a German cohort [44], while other groups could not 
demonstrate such association [45, 47, 49, 50]. 
The importance of PRR mutations in the development of IBD is further supported by the 
findings that a TLR9 polymorphism (-1237T/C) was significantly higher in patients with CD 
[50], while polymorphism in the CARD9 gene (rs10870077), which encodes an adaptor 
molecule of PRR signaling, was associated with both CD and UC [51, 52]. 
Beside PRR genes GWASs have identified several other susceptibility genes, which has 
led to better understanding of the pathomechanism. The identification of IBD associated 
polymorphisms in autophagy-related 16-like 1 (ATG16L1) and immunity-related GTPase 
family M protein (IRGM) genes has revealed that impaired autophagy, and the consequent 
defects in innate immune responses to intracellular pathogens may be critical components of 
the chronic inflammation in IBD [53-56]. IBD associated alterations in X-box-binding protein 
1 (XBP1) and orosomucoid-like 3 (ORMDL3) genes imply that changes in the unfolded 
protein response (UPR) and the failure to manage endoplasmic reticulum stress may also 
contribute to the pathogenesis, for example due to increased apoptosis of Paneth cells [57, 
58]. Mutations in the mucin genes (e.g. MUC1, MUC19) or in the prostaglandin receptor EP4 
gene (PTGER4) can lead to impaired mucosal barrier functions [51, 59], while genetic 
variations in the IL18RAP [52], IL23R [60, 61], STAT3 [62] or SMAD3 [51] genes highlight 
the importance of failures in the adaptive immune responses in IBD. 
 
2.2. Immune dysregulation 
 
The intestinal mucosa is continuously exposed to a vast number of antigens (both 
dietary and microbial), which are recognized by the mucosal immune system. Under normal 
circumstances it distinguishes between beneficial and pathogenic microbes - it tolerates 
normal commensal bacteria, while eliminates invading pathogens. Today it is widely accepted 
that abnormal immune regulation is a key factor in the pathomechanism of IBD and 
alterations in both innate and adaptive immunity have been observed. This section shortly 
overviews the key players of the immune system and their contribution to IBD. For more 
comprehensive recent immunological reviews see e.g. [63-66]. 
The pattern recognition receptors (PPRs) play a key role in the bacteria-host interaction. 
These innate immune receptors are expressed by different cells of the intestinal mucosa (like 
dendritic cells (DCs), macrophages and intestinal epithelial cells (IECs)), and recognize 
conserved microbial structures (PAMPs). Probably the best-characterized family of PRRs are 
the Toll-like receptors (TLRs). This family comprises 13 members in mammals, ten in 
humans (TLR1-10) and 12 in mice (TLR1-9, TLR11-13) [67]. Most TLRs (TLR1, 2, 4, 5, 6 
and 11) are localized on the cell surface, where they recognize mainly bacterial cell wall 
components (LPS of Gram negative bacteria by TLR4, lipoproteins from Gram-positive 
bacteria by TLR1, 2 and 6, flagellin by TLR5), while some members in this family are 
localized intracellularly in the endosomes (TLR3, 7, 8 and 9) and recognize viral or bacterial 
nucleic acids [68, 69]. 
The family of NOD-like receptors (NLRs) includes 23 members in humans and 34 in 
mice [31, 69]. These cytoplasmic receptors contain a leucine-rich repeats (LRR) domain, 
which senses bacterial ligands, a central NOD domain (also called NATCH domain) required 
for activation and an N-terminal effector domain that mediates interactions with other 
signaling proteins. Based on the effector domain five subfamilies can be distinguished, these 
are NLRA (also called CIITA, which contains an acidic domain), NLRB (or NAIP, which 
contains baculovirus inhibitor repeats (BIR)), NLRC (or NOD, which possesses a caspase 
recruitment domain (CARD)), NLRP (or NALP, contains a pyrin domain (PYD)) and NLRX 
(contains an unidentified domain) [30, 69, 70]. 
Further PRRs are the retinoic acid-inducible gene-I (RIG-I)-like receptors (RLRs), like 
RIG-I, MDA5 and LGP-2, which are also intracellularly localized and sense primarily viral 
RNAs [71], and the C-type lectin receptors (CLRs), including Dectin-1, Dectin-2, mannose 
receptor, C-type lectin receptor DC-SIGN and Mincle, which play an essential role in 
antifungal immunity [72, 73]. 
As mentioned above, PRRs are expressed by various cells in the intestinal mucosa and 
their activation modulates inflammatory processes at various levels. At first, they regulate the 
barrier function of the mucosa, which is the front line of defense against intestinal pathogens. 
The damage of IECs and their barrier function leads to an increased penetration of the 
microbes in the gut wall, which in turn activates immune cells and causes inflammation. 
Several studies demonstrate barrier disturbance in both animal colitis models and in patients 
with CD and UC [74-77]. In IBD IEC permeability increases both transcellularly (in which 
TNF-α has a major role) [78] and paracellularly via junctional complexes. For instance, an 
impaired tight junction sealing due to upregulation of claudin 2 and downregulation of claudin 
5, claudin 8 and occludin was reported in patients with active CD [79]. PRRs are involved in 
the modulation of epithelial integrity. Activation of TLR2 enhances the transepithelial 
resistance in vitro (through redistribution of the tight junction protein ZO-1) and increases 
tight junction-associated IEC barrier integrity in vivo [80, 81], and recent evidence suggest 
that NOD2 potentiates the TLR2-induced improvement of mucosal barrier [82]. Beside TLR2 
also TLR9 has been shown to enhance transepithelial resistance [83], while the action of 
TLR4 is still not clear, since both improvement and disruption of the mucosal barrier have 
been described upon stimulation with LPS [82, 84]. 
PRRs are also able to enhance mucosal barrier functions via stimulating the secretion of 
antimicrobial peptides (AMPs), like cathelicidin and defensins. These peptides are secreted 
into the gut lumen by leukocytes and epithelial cells and regulate host microbial interaction 
and the composition of the commensal microbiota [74, 85]. The expression of α-defensins by 
Paneth cells is associated with NOD2 signaling [86] and decreased α-defensin production was 
observed in CD patients with NOD2 mutations [87, 88] although it has also been raised that 
reduced α-defensin production is only the consequence, and not the cause of the inflammation 
[89]. Beside regulating the α-defensin production, PRRs stimulate also the secretion of other 
AMPs. The activation of TLR4- and TLR2 increased β-defensin-2 expression by human IECs 
[90] and the expression of cathelicidin by mucosal macrophages was connected with TLR9 
signaling in mice [91]. Taking the manifold effects of PRRs on AMP production into 
consideration, it is not unexpected that PRR signaling can also shape the structure of the gut 
microbial community. For example in TLR2 KO mice the proportion of Firmicutes and 
Proteobacteria was significantly higher and lower, respectively, in the gut microbiota [92], 
while NLRP6 deficiency was associated with increased representation of Prevotellaceae [93]. 
Hence, not only microbes can influence the host immune response via PRRs, but vice versa, 
PRRs can also influence the make up of the microbiota and control the load of commensal 
bacteria. 
The healing of the intestinal mucosa in case of epithelial injury is essential to restore 
barrier functions. The controlled migration, proliferation and functional differentiation of 
IECs is regulated by various growth factors (including epithelial growth factor (EGF), TGF-α, 
TGF-β and fibroblast growth factor (FGF)), chemokines, regulatory cytokines (e.g. IL-6, IL-
22) and trefoil peptides [94]. Several results suggest that epithelial restitution is influenced by 
PRRs. TLR2 induces gap junctional intercellular communication via connexin-43, and 
controls IEC restitution during acute and chronic inflammatory damage [95]. Similarly to 
TLR2, TLR4 is also likely to improve mucosal healing. Decreased epithelial proliferation was 
found in TLR4 deficient mice [96] and antibody directed against TLR4 impaired mucosal 
healing due to reduced expression of cyclooxygenase-2, prostaglandin E2 (PGE2) and 
amphiregulin [97]. Beside TLRs also NLRs are able to modulate the regeneration of the IECs. 
NLRP3 (also known as NALP3 or cryopyrin), which is one of the best-characterized NLRPs, 
recruits ASC (apoptosis-associated speck-like protein) and pro-caspase-1 into a large protein 
complex (inflammasome) to mediate the secretion of IL-1β and IL-18 [66]. Zaki et al. [98] 
demonstrated that NLRP3-, ASC- and caspase-1 KO mice are highly susceptible to DSS-
colitis, which is due to the decreased maturation and secretion of IL-18, and the consequent 
reduction of epithelial regeneration. 
Beside regulating mucosal barrier functions, PRRs on DCs and macrophages are key 
factors in innate immunity. 
DCs express a wide range of PRRs and interpret microbial patterns to direct other 
immune cells towards immunity or tolerance. They are able to sample luminal antigens 
directly by forming transepithelial dendrites [99]. Upon encounter with pathogens, DCs 
undergo rapid maturation characterized by upregulated expression of major histocompatibility 
complex (MHC) and co-stimulatory molecules (like CD80, CD86, CD40) and production of 
pro-inflammatory cytokines (IL-1, IL-6, IL-12, IL-23, TNF-α). Then they migrate to the 
draining lymph nodes, where promote the proliferation and differentiation of naïve CD4 T-
cells to Th1, Th2 or Th17 subsets. On the other hand, DCs are also important for the 
maintenance of homeostasis and tolerance against the commensal microbes via the production 
of anti-inflammatory cytokines such as IL-10 and TGF-β and the production of tolerogenic 
regulatory T (Treg) cells [63, 100, 101]. 
Several studies demonstrate the active involvement of DC in the pathogenesis of IBD. 
The number of DCs expressing the maturation markers CD80, CD83, CD86 and CD40 is 
elevated in CD and UC [102-105]. DCs express also higher levels of TLR2 and TLR4 [102] 
and accordingly, show exaggerated response to LPS in IBD [106]. This may result in false 
recognition of commensal bacteria and induction of pro-inflammatory immune responses. 
Beside secreting higher amounts of pro-inflammatory cytokines, DCs are also less able to 
induce tolerogenic Foxp3+ Treg cells in CD [107]. 
The role of intestinal macrophages in IBD has also been intensively studied [63]. 
Similarly to DCs, macrophages also present antigens to T-cells and induce their 
differentiation to pro- or anti-inflammatory subsets [108, 109]. M1 macrophages produce pro-
inflammatory cytokines TNF-α, IL-12 and IL-23, and promote a polarized Th1 response, 
while M2 macrophages are characterized by production of IL-10 [109]. Thus, M2 
macrophages may have important role in maintaining intestinal homeostasis and alterations in 
the levels of macrophages and their cytokines can contribute to the pathomechanism of colitis 
in animal models and in IBD. Accordingly, Smith et al. [110] found different cytokine 
profiles released by macrophages in healthy controls and CD patients after stimulation with 
heat-killed Escherichia coli or with the TLR2 ligand Pam3CSK4. 
It is noteworthy, that Kamada et al. [111] observed the infiltration of unique CD14+ 
intestinal macrophages in the mucosa of CD patients at both inflamed and non-inflamed sites. 
These macrophages produced larger amounts of pro-inflammatory cytokines, such as IL-6, 
IL-23 and TNF-α, than typical intestinal resident macrophages, and the authors raised the 
possibility that CD14+ macrophages may play a key role in the predominance of Th1 immune 
response found in CD [111]. 
The role of macrophage migration inhibitory factor (MIF), an other pro-inflammatory 
cytokine originating from both T-cells, innate immune cells and epithelial and endothelial 
cells in the pathomechanism of IBD is emerging [112, 113]. MIF promotes the recognition of 
LPS and Gram-negative bacteria by upregulating the basal expression of TLR4 in the 
macrophages, thus serves as a key factor in the initiation of innate immune response [114]. 
The release of MIF stimulates the release of inflammatory cytokines, potentiates the 
recruitment of neutrophils to the inflammatory site and triggers metalloprotease (e.g. MMP-
13) expression, leading to inflammation and tissue damage [112]. The expression of MIF was 
increased in DSS-induced colitis and administration of anti-MIF antibody significantly 
improved the DSS-induced symptoms [115]. Moreover, the levels of MIF in the sera of UC 
patients were significantly higher [116], which suggests that anti-MIF therapy may be a new 
therapeutic approach in IBD. Since increased MIF-expression is also associated with 
tumorigenesis [117], it is tempting to speculate that inhibition of MIF may also reduce the risk 
of colon cancer related to chronic inflammation. 
As depicted above, the activation of PRRs expressed on innate immune cells and the 
consequent release of inflammatory cytokines results in different T-cell pattern. In CD mainly 
the Th1 cytokines (IL-12, TNF-α, IFN-γ), while in UC predominantly Th2-associated 
cytokines (like IL-5 and IL-13) are dominating [118-120], and recognition of the importance 
of these cytokines led to the development of anti-cytokine biologic agents in the therapy of 
IBD. However, it has to be emphasized that the cytokine profile of these diseases is much 
more complex and even individual cytokines may possess diverse or opposing action in 
different clinical and immunological settings [64]. 
Furthermore, the recent discovery of the Th17 lineage has raised a new paradigm. Th17 
cells differentiate from naïve CD4 T-cells, which process is induced and regulated by various 
cytokines, like IL-1β, IL-6, IL-21, IL-23 and TGF-β [121]. It has been revealed that Th17 
cells, producing IL-17 and other pro-inflammatory cytokines play an essential role in the 
development of colitis in both mice and humans [122-124]. 
The activation of PRRs (both TLRs and NLRs) by the intestinal microbiota is essential 
for the development of Th17 cells, which is clearly demonstrated by the marked reduction of 
the Th17 cell number in germ-free mice [125, 126]. Accordingly, stimulation of TLR5 on 
lamina propria DCs promoted the differentiation of Th17 cells [127], while TLR9-deficient 
mice had decreased number of lamina propria Th17 cells [128]. Moreover, the stimulation of 
DCs with MDP has been shown to enhance NOD2-mediated production of IL-1β and IL-23, 
which in turn promoted the IL-17 production by memory T-cells [129]. These results 
highlight the importance of PRRs also for adaptive immunity. In addition, although originally 
PRRs were thought to regulate innate immunity and only indirectly the adaptive responses, it 
turned out that also T- and B-cells express PRRs, and TLR or NLR agonists are able to 
directly influence their functions [32, 130, 131]. 
In summary, disruption of the mucosal barrier, increased and altered activation of DCs 
and macrophages, impaired balance between pro- and anti-inflammatory cytokines and 
polarisation of the adaptive immune response towards the effector T-cells all contribute to the 
pathomechanism of IBD, and PRRs are an important link between the participants of this 
complex system. 
 
2.3. The microbiota 
 
The human gut is inhabited by ~ 100 trillion bacteria, which can consist of more than 
1000 species overall and at least 160 species in each individual [132]. This indigenous 
bacterial community (the microbiota) is influenced by several factors (like diet, age or health 
status) and varies between individuals, although mainly only at the levels of strains and 
species, while most of the bacteria are members of the Bacteroidetes and Firmicutes phyla 
[133, 134]. The microbiota plays a fundamental role in energy metabolism and immunity, 
however, its role has also been implicated in several diseases, e.g. obesity, insulin resistance 
and IBDs (recently reviewed e.g. by [135-137]). 
In the last decades considerable efforts have been made to identify a specific pathogen 
in IBD, and some bacteria (e.g. Mycobacterium avium spp. paratuberculosis or adherent-
invasive Escherichia coli (AIEC)) have been proposed as causative agents, mainly in CD 
[138-140]. Moreover, various clinical studies were conducted to analyze the potential 
therapeutic effect of different antibacterial regimens (usually with the agents clarithromycin, 
metronidazole, ciprofloxacin or rifaximin), but the results are conflicting [141, 142]. Now it is 
generally assumed, that instead of one (or few) distinct pathogen(s) an altered composition of 
gut flora, resulting in dysbiosis, and an overactive immune response may lead to chronic 
intestinal inflammation [143]. 
It is well established that the microbiota in IBD patients differs significantly from that of 
healthy people. One main difference is the decreased representation of the Firmicutes phylum. 
A reduction of the Clostridium leptum and coccoides groups (also known as Clostridium 
cluster IV and XIVa, respectively), and in particular the decreased amount of 
Faecalibacterium prausnitzii was observed by several groups [144-148]. Indigenous 
Clostridia may possess anti-inflammatory properties by inducing IL-10 expressing Foxp3+ 
CD4+ Treg cells in the colon [149]. Moreover, the loss of these bacteria may result in a 
decreased butyrate production, which is one of the most important bacterial products in the 
gut and exerts various anti-inflammatory effects via regulating the migration of neutrophils, 
inhibiting the production of pro-inflammatory cytokines and increasing the expression of tight 
junction proteins in colon epithelia [136, 150]. 
Another important genus in this phylum is the Lactobacillus, which contains several 
probiotic strains. Some of them (e.g. the Lactobacillus rhamnosus GG strain) may possess 
beneficial effects in IBD [151] and recent evidences indicate that Lactobacillus salivarius 
Ls33 is able to inhibit experimentally induced colitis in a NOD2-dependent manner [152]. 
Furthermore, von Schillde et al. identified a Lactobacillus paracasei prtP-encoded protease 
named lactocepin, which degrades the pro-inflammatory chemokine IP-10 (interferon gamma-
induced protein 10) and consequently alleviates colonic inflammation [153]. Thus, a reduced 
amount of Lactobacillus may contribute to the pathogenesis of IBD. Indeed, such alterations 
in the microbiota were observed by several authors [93, 145], though increased amounts [144] 
or no change of Lactobacillus levels [147] have also been reported. 
Alterations in the Bacteroidetes phylum are also likely to contribute to the chronic 
inflammation. An increased representation of the Prevotellaceae has been documented in IBD 
patients [154, 155] and recently also in the intestines of mice with an impaired innate 
immunity [93]. It is assumed that these bacteria are colitogenic via producing sulfatases, that 
degrade mucus oligosaccharides and disrupt mucosal barrier function [156]. 
In contrast, Bacteroides fragilis is supposed to exert anti-inflammatory effects. Its 
Polysaccharide A (PSA) component has been shown to inhibit Helicobacter hepaticus-
induced experimental colitis in mice [157] and to directly induce the anti-inflammatory 
function of Foxp3+ Treg cells by acting on TLR2 [158]. Although early observations 
suggested a higher abundance of Bacteroides fragilis in IBD patients [159], recent studies 
found lower levels of this commensal [146, 147]. 
Similarly to Lactobacilli, Bifidobacteria from the Actinobacteria phylum also contain 
several probiotic strains and exert anti-inflammatory effects. Bifidobacteria had beneficial 
effect in both animal models [160] and in patients with UC and CD [161-163], while lower 
count of Bifidobacteria was measured in IBD [147]. One potential protective mechanism is 
the activation of Tregs, as it has been observed in the case of Clostridia and B. fragilis (see 
above). The probiotic Bifidobacterium breve induced IL-10-producing Treg type 1 cells by 
activating intestinal CD103+ dendritic cells via the TLR2/MyD88 pathway [164]. Another 
strain, Bifidobacterium lactis significantly decreased the colonic expression of various pro-
inflammatory, dendritic and T-cell markers, like IL-6, TNF-α, COX-2, CD40-L or IFN-γ in 
mice [160]. 
In summary, there is growing evidence that an imbalance between colitogenic (e.g. 
AIEC) and tolerogenic bacteria (like Clostridia, Lactobacilli and Bifidobacteria) has a major 
role in the pathomechanism of IBD. Colitogenic bacteria can damage the epithelial barrier 
functions either directly or via producing toxins. For instance AIEC strain LF82 disrupts the 
tight junction protein zonula occludens-1 [165] and through binding to the cell adhesion 
molecule CEACAM 6 can lead to abnormal expression of claudin 2 [166], while 
enteropathogenic Escherichia coli (EPEC) induces epithelial cell apoptosis by producing a 
bacterial toxin called cycle inhibiting factor [167]. Both results in an increased intestinal 
permeability, which permits the penetration of luminal antigens and microbes, that can 
stimulate pro-inflammatory responses. 
However, the altered microbial flora can also induce inflammation indirectly, via 
reduced production of anti-inflammatory bacterial metabolites, like butyrate and other short-
chain fatty acids (see above) [136] or via an altered metabolism of bile acids. Primary bile 
acids cholic acid and chenodeoxycholic acid are transformed by intestinal bacteria to their 
secondary forms, deoxycholic acid and lithocholic acid, which can disrupt intestinal barrier 
functions [168, 169]. The recent results of Duboc et al. provide direct evidence of the 
connection between dysbiosis, bile acid dysmetabolism and chronic colonic inflammation 
[144]. They found a marked decrease in bacteria of the Firmicutes phylum and altered levels 
of secondary and conjugated bile acids in the faeces of patients with IBD. 
 
2.4. Environmental factors 
 
Environmental factors may also play a role in the pathogenesis of IBD. As mentioned 
earlier, the composition of the microbiota is substantially influenced by diet and other life 
style factors [170, 171], and accordingly, dietary changes may contribute to the 
pathomechanism of IBD. Indeed, it was demonstrated that consumption of a diet high in 
saturated (milk derived)-fat promoted colitis in IL-10 knock out mice [172]. The triggering 
factor was presumably the increased taurine-conjugation of bile acids, which increased the 
availability of organic sulfur and the amount of the sulfite-reducing microbe Bilophila 
wadsworthia, which in turn induced Th1 immune responses. Moreover, Kim et al. [173] 
reported that high fat diet altered the microbiota leading to an increased lumenal LPS content 
in the colon, which increased intestinal permeability and induced inflammation through a 
TLR4 signaling pathway. 
In addition, vitamin D deficiency [174], as well as active and passive tobacco smoking 
[13, 175], air pollution [176] or improved domestic hygiene and sanitation [177] are 
additional factors that may modify the homeostasis of the intestinal mucosa. The 
observations, that IBD is common in Western countries, while uncommon in less developed 
areas, raised the intriguing hypothesis that improved hygiene and the consequent loss of 
routine exposure to parasitic worms (helminths) may play an important role in the 
pathomechanism of IBD [178]. 
Helminth infections may have several beneficial effects on the immune system 
(reviewed by [179, 180]). They induce the formation of regulatory DCs, regulatory Treg cells 
and the production of anti-inflammatory cytokines (IL-10, TGF-β), while decreasing the 
formation of effector T-cells and pro-inflammatory cytokines (like IFN-γ, IL-17 or IL-12/23). 
Moreover, they seem to alter the composition of the microbiota and promote the growth of 
probiotic Lactobacillaceae [181]. 
 
3. Therapy 
The traditional therapeutic concept of CD is based on the so-called "step-up" approach: 
less toxic drugs (but often less effective), are given in mild disease, whereas more effective 
(but potentially more toxic) agents are given in severe disease or in patients who are 
unresponsive to first-line therapy. Common conventional medications currently start with 5-
aminosalicylic acid drugs, corticosteroids (prednisolone, methylprednisolone, budesonide), 
immunosuppressive agents (azathioprine, 6-mercaptopurine, methotrexate, cyclosporin, 
tacrolimus) [182]. The more effective biological therapies are usually considered as a last 
option and only in case of refractory diseases, because they often cause severe adverse effects 
[183, 184]. This strategy is recommended by current guidelines [185]. 
However, the natural course of the disease is not likely to be modified by conventional 
treatment [186]. Since anti-TNF-α therapy can induce and maintain clinical remission and 
mucosal healing, early administration of anti-TNF-α biological agents may prevent late 
complications [187]. Consequently, the question has been raised recently: whether to maintain 
or to reverse the traditional therapeutic pyramid [188]. On the other hand, it also has to be 
kept in mind that majority of CDs have benign course and immune modulators and biologics 
have severe adverse effects, that may result in increased risk of infections and malignant 
diseases (lymphoma) [189]. Consequently, treatment of the patients, who have a mild, benign 
course of the disease with highly potent biologics, such as TNF-α antagonists is not a good 
therapeutic choice, because of the risk of adverse effects. 
The basic therapy of IBD has involved aminosalicylic formulations and glucocorticoids 
for UC as well as CD. Immunosuppressive agents such as azathioprine and 6-mercaptopurine 
were shown to be effective in both CD and UC, while methotrexate proved to be effective as a 
steroid-sparing agent in CD. On the other hand, cyclosporine induced a pronounced 
therapeutic effect in severe, active UC [190, 191]. 
A milestone in the therapy of CD was the introduction of infliximab, the first 
monoclonal antibody against TNF-α, proved to be effective in induction of remission in CD 
patients who had been refractory to other therapeutic agents [192]. Later, it was demonstrated 
that both adalimumab, and certolizumab, monoclonal antibodies against TNF-α, maintained 
the clinical remission [193, 194]. 
However, surprisingly, etanercept (another anti-TNF-α agent, that fuses the TNF 
receptor to the constant end of the IgG1 antibody) failed to exert similar beneficial effect in 
CD [190, 195]. 
As mentioned above, anti-TNF-α agents may induce several side effects. Moreover, 
among the primary responders only a third of patients will maintain remission after 1 year 
[196], and the therapy is often limited by a loss of efficacy. Therefore, finding novel targets 
and the development of novel therapeutic strategies became an urgent need. 
The strategy to find new targets is based on the main pathological alterations that 
characterize IBD. Since the disease is caused by a combination of factors, including genetic 
susceptibility, immune dysregulation, barrier dysfunction, and the change in microbial flora, 
the new therapeutics aim to correct or restore 1./ the genetic alterations, 2./ the immune 
dysregulation, 3./ the barrier dysfunction and mucosal resistance 4./ the altered composition of 
gut flora (Fig. 1.). 
 
3.1. Correction of genetic alterations 
 
Under normal, healthy condition the intestinal mucus layer prevents exposure of IECs to 
luminal bacteria. Several mechanisms are involved in protection of intestinal epithelium 
against luminal microbiota, e.g. defensins (secreted by Paneth cells) and the production of 
immunoglobulin A (IgA). PRRs are involved in the production of cytokines necessary for the 
development of immunity and have crucial role in innate microbial sensing by IECs, DCs and 
macrophages [30]. Their activation initiates NF-κB and MAPK signaling pathways resulting 
in the production of pro-inflammatory cytokines and antimicrobial peptides [5, 197]. In 
addition, autophagy has a crucial role in the maintenance of intracellular homeostasis 
preventing abnormal accumulation of protein aggregates, intracellular components, such as 
organelles, apoptotic bodies, and microbes [198]. One of the key proteins involved in the 
execution of the autophagic process is ATG16L1 [199]. 
Though a large number of genetic loci have been found to be associated with CD, the 
polymorphism of two genes, NOD2/CARD15 [200] and ATG16L1 seem to have particular 
importance in the development of the disease [201]. While in healthy subjects ATG16L1 
encodes threonine at amino acid position 300 (ATG16L1*300T), ATG16L1 encoding alanine 
(ATG16L1*300A) instead of threonine at the same position increases the risk of the 
development of CD, due to impairement in bacterial capture by autophagy [202]. 
Moreover, patients with CD showed decreased expression of mucosal TLR3 and 
increased expression of TLR4, which results in downstream release of inflammatory 
modulators, for example TNF-α and IL-1 [203]. Consequently, stimulation of the TLR3 or 
NOD2 pathway may represent a new approach of the therapy of IBD. Experimental data 
suggest that activation of TLR3 (e.g. by synthetic viral RNA) or NOD2 were effective for 
prevention of dextran sodium sulphate (DSS)-induced acute colitis in the mouse [204-206], 
which implies that stimulation of TLR3 or NOD2 signaling may represent a new, successful 
therapeutic strategy for the treatment of CD in those patients who show reduced expression of 
TLR3 or carry NOD2 mutations [207]. On the other hand, blocking TLR signaling may 
represent another approach for IBD treatment, because TLR2 and TLR4 are up-regulated in 
IBD [208]. Experimental data suggest that TLR4 blockade decreased inflammation in DSS-
induced colitis in mice, but also interfered with colonic mucosal healing, since anti-TLR4 
antibody treatment during recovery from DSS colitis resulted in defective mucosal healing (as 
described above) [209]. 
Attempts have been made to develop new TLR4 signaling inhibitors. Recently, 
arylidenemalonate derivatives were found to suppress LPS-induced production of NF-κB, 
TNF-α, IL-1β and nitric oxide [210], suggesting its potential therapeutic value for various 
inflammatory diseases. However, their real role in IBD remains to be clarified. 
 
3.2. Restoration of immune dysregulation 
 
Today it is widely accepted that abnormal immune regulation is a key factor in the 
pathomechanism of IBD and alterations in both innate and adaptive immunity have been 
observed. Dysregulation of mucosal immunity in IBD leads to an overproduction of 
inflammatory cytokines and trafficking of effector leukocytes into the intestinal mucosa, thus 
resulting in an uncontrolled intestinal inflammation. Under homeostatic condition there is a 
balance between regulatory (Treg) and effector T-cells (Th1, Th2 and Th17). Mucosal 
inflammation is induced either by an increase in the effector T-cell population and an 
increased production of pro-inflammatory cytokines (such as TNF-α, IFN-γ, IL-1, IL-6, IL-
12, IL-17, IL-23) or a reduced function of Treg cells and decreased level of anti-inflammatory 
cytokines (e.g. TGF-β, IL-4, IL-10 or IL-11) produced by different immune cells located in 
the lamina propria of the intestinal mucosa. Cytokines may therefore be targets for IBD 
therapy [211]. Moreover, elimination of intestinal inflammation may be achieved either by 
reduction of effector T-cell populations or by increasing regulatory T-cell activity [5, 212]. 
Several reviews have been published recently on the potential therapeutic agents in IBD 
that target the immune dysregulation [7, 12, 188, 190, 211, 213-218]. 
Restoration of the immune dysregulation may be achieved by several mechanisms, such 
as inhibition of 1./ pro-inflammatory cytokines, 2./ Th1 polarisation and proliferation, 3./ T-
cell stimulation (anti-CD3 therapy), 4./ cell adhesion, as well as 5./ by immune stimulation 
(Granulocyte Macrophage Colony Stimulating Factor /GM-CSF)/ and Granulocyte Colony 
Stimulating Factor /G-CSF/ and 6./ by increase of anti-inflammatory cytokines. 
 
3.2.1. Inhibition of pro-inflammatory cytokines 
 
Inhibitors of TNF-α 
 
TNF-α is a fundamental mediator of this abnormal immune response. TNF-α has two 
forms, a transmembrane and soluble form, and its action is mediated by 2 receptors, TNF-R1 
(TNF receptor type 1, CD120a or p55/60) and TNF-R2 (TNF receptor type 2, CD120b or 
p75/80) [219] resulting in complex and differential actions. While the pro-inflammatory 
effects of TNF-α are mediated by TNF-R1, the immunoregulatory functions are independent 
from this receptor. Consequently, selective inhibitors of TNF-R1 that reduce the pro-
inflammatory function of TNF-α without affecting its immunoregulatory effects, may 
represent a new therapeutic approach of IBD. 
In the last 15 years, biological agents targeting TNF-α have significantly improved the 
therapy of IBD refractory to conventional drugs. The efficacy of this therapy alone reflects the 
pleiotropic effects of TNF-α. 
Infliximab, a monoclonal chimeric antibody, targeting human TNF-α, became the first 
monoclonal antibody available for the treatment of CD and UC. The potency of this agent in 
moderate-to-severe CD and UC has been one of the most important advances in the treatment 
of IBD. 
Infliximab also induces T-cell apoptosis, that contributes to its therapeutic effect [220]. 
Namely, in the gut, there is a tight control of activation and expansion of T-cells. T-cell 
expansion is limited by apoptosis, and T-cell resistance to apoptosis with consequent T-cell 
expansion was observed in patients with IBD, which may contribute to the pathomechanism 
[221]. Hence, it may be raised that induction of apoptosis in T-cells and other effector cells 
may have therapeutic importance in the treatment of IBD and pro-apoptotic signaling might 
be a target for drug development [5]. 
It has been shown that some anti-TNF-α agents induce apoptosis in monocytes and 
lymphocytes both in vitro and in vivo [222, 223]. Consequently, apoptosis-induction seems to 
be an important part of the therapeutic action of TNF-α antagonists and differences in their 
apoptotic efficacy might contribute to the differences found in their clinical efficacy. In 
addition to infliximab, several other therapeutic agents that are effective in the treatment of 
IBD, including corticosteroids, sulfasalazine, azathioprine, 6-mercaptopurine and anti-IL-12 
antibody, induce apoptosis of activated T-cells [222, 224-226]. 
Adalimumab, a fully human IgG1 monoclonal antibody to TNF-α, was found to be 
effective in patients with CD refractory to conventional therapy and in patients with an 
attenuated response to infliximab [211, 227, 228]. Recent study showed that adalimumab 
could induce and maintain clinical remission in patients with moderate-to-severe UC as well, 
who did not have a satisfactory response to steroids or immunosuppressive agents [229]. 
Certolizumab and certolizumab pegol (its PEGylated Fab' fragment with increased 
plasma half-life) are humanized TNF-α monoclonal antibodies. Majority of the human studies 
demonstrated their effectiveness in maintenance of response and remission in CD [230, 231]. 
However, Sandborn et al. failed to confirm the effectiveness of certoluzimab after 6 weeks 
treatment [232]. 
Etanercept is a genetically engineered fusion protein consisting of two recombinant 
human TNF p75 receptors linked to an Fc portion of human IgG1 fragment. It was found to 
be ineffective for the treatment of patients with moderate to severe CD in the same dose range 
that was effective in rheumatoid arthritis [233]. 
CDP571, an immunoglobulin G4 humanized monoclonal anti-TNF-α antibody showed a 
slight and short lived reduction in clinical activity of UC [234]. It proved to be less effective 
than infliximab and further clinical development of CDP571 for the treatment of CD has been 
discontinued (see review [194]). 
Novel TNF inhibitors have been developed, such as golimumab, dersalazine, HMPL-
004 and ozoralizumab (ATN-103). These compounds are in various phases of the clinical trial 
process, and their real therapeutic values have to be determined [12]. In addition, recently a 
vaccine against TNF-α has been developed (TNF-α kinoid, Debio-01512), as a new 
mechanism for inhibition of TNF-α [196], and phase I/II clinical trials in patients with 
moderate to severe CD were found to be promising [235, 236]. 
 
Inhibition of IL-6 
 
IL-6 has a fundamental role in immune regulation and inflammation. The IL-6 
receptor (IL-6R) system has both a membrane-bound (IL-6R) and a soluble form (sIL-6R). 
Increased serum concentrations of IL-6 and sIL-6R have been shown to correlate to clinical 
activity of CD, and animal models have strongly suggested the therapeutic potential of anti-
IL-6R monoclonal antibody. For example, anti-IL-6R monoclonal antibody reduced the 
symptoms of colitis in Th1 cell-mediated murine colitis model. Similarly, blockade of sIL-6R 
in vivo by a newly designed gp130-Fc fusion protein resulted in reduction of colitis activity 
and induction of apoptosis, indicating that sIL-6R suppresses mucosal T-cell apoptosis. 
Accordingly, it was shown recently that IL-6 induces the anti-apoptotic genes BCL2 and 
BCL-XL [237]. These results suggest the therapeutic potential of anti-IL-6R monoclonal 
antibody in CD [237, 238]. 
Tocilizumab (also known as MRA) is a humanized IL-6 receptor antibody, recognizes 
both the membrane-bound and the soluble form of IL-6R and specifically blocks IL-6-induced 
actions [239]. Tocilizumab is expected to ameliorate the autoimmune inflammatory diseases 
characterized by IL-6 overproduction and has been developed as a therapeutic agent for 
rheumatoid arthritis (see review [240]). Tocilizumab treatment of patients with active CD 
induced reduction of the disease activity index compared to the placebo group, however, 
remission of the disease was archived only at very low proportion of the patients [241]. The 
beneficial effect of tocilizumab was confirmed by Nishimoto [242]. 
 
Inhibition of IL-13 
 
IL-13 has been shown to be pathogenic in IBD, particularly in UC. It impairs the 
function of the epithelial barrier and also causes apoptosis of epithelial cells [10, 11, 243, 
244]. IL-13 overexpression in the inflamed mucosa is particularly characteristic for UC and 
IL-13 is considered as the major effector cytokine in UC [245]. 
The anti-IL-13 antibody anrukinzumab (IMA-638) as well as tralokinumab (CAT-354), 
a fully human anti-IL-13 antibody are under clinical studies (phase IIa) in patients with mild 
to moderate UC. QAX576, another fully human antibody against IL-13, is in phase I/II trials 
in patients with CD, the final results are pending [246, 247]. 
 
Inhibition of mitogen activated protein kinases (MAPKs) 
 
Expression of pro-inflammatory cytokines, which are critical in the pathogenesis of 
IBD, is regulated by one or more MAPK pathways. Accordingly, activation of several MAPK 
members was found in biopsies from the inflamed mucosa of CD patients [248]. 
CNI-1493 (semapimod), inhibitor of JNK/p38MAP kinases, showed significant 
clinical improvement of severe CD, confirming the potential role of inflammatory MAPKs in 
the pathogenesis of CD [249]. In contrast, a highly potent inhibitor of p38 MAPK, BIRB 796 
(doramapimod) was studied in chronic active CD in a multicenter, multinational trial with 
placebo control, and the results failed to show evidence for clinical efficacy [250]. 
Concerns with the use of MAPK inhibitors have been raised, for example inhibition of 
p38 and 42/44 MAPK reduces normal bactericidal activity of neutrophils [251]. Moreover, 
ubiquitous presence of the MAPK pathways and their involvement in several processes 
suggests that MAPK inhibition should be selective for an isoform, rather than general. 
 
New avenues against pro-inflammatory cytokines or downstream signaling pathways 
 
Currently, several novel agents have been developed to target either pro-inflammatory 
cytokines or downstream signaling pathways. Pro-inflammatory cytokines IL-17, IL-18 and 
IL-21 were found to be elevated in the inflamed intestinal mucosa of patients with IBD [252-
254]. Monoclonal antibodies developed against these cytokines are currently in phase I/II 
clinical trials in patients with CD. Unexpectedly, secukinumab (AIN 457) targeting IL-17 in 
double-blind, placebo controlled study in patients with CD worsened the disease compared 
with placebo [255]. In contrast, inhibitor of the release of IL-17, vidofludimus (4SC-
101/SC12267) showed beneficial effect in a single-arm, open-label study, indicating that it 
may be useful in maintaining clinical remission both in patients with CD and UC [256]. 
Further investigation is needed to clarify the modulatory role of IL-17 in IBD.  
On the other hand, gut inflammation can also be restricted by blocking the downstream 
signaling pathways mediated by cytokines. Signaling molecules that interact with cytokine 
receptors are the Janus kinases (JAK), JAK1, JAK2 and JAK3, which play a fundamental role 
in the development and differentiation of immune cells. 
Tofacitinib, inhibitor of JAK3 was developed recently [257], but various clinical 
efficacies have been experienced. A multicentre, double-blind, placebo controlled study with 
tofacitinib in patients with moderate to severe active CD showed no clinically significant 
response following 4 weeks of treatment compared with placebo, but in patients with 
moderate to severe UC it showed improvement in both clinical response and remission rates 
[258, 259]. 
 
3.2.2. Inhibition of TH1 polarisation and proliferation 
 
Inhibition of IL-2 
 
Inhibition of the binding of IL-2 to the IL-2 receptor results in inhibition of the 
growth, proliferation and differentiation of T-cells to 'effector' T-cells. 
Basiliximab (chimeric monoclonal antibody) and daclizumab (humanized monoclonal 
antibody) are targeted against the α-chain of the IL-2 receptor (CD25), and inhibit the binding 
of IL-2 to the IL-2 receptor. However, daclizumab failed to induce a significant action in UC 
[260]. Neither basiliximab increased the effect of corticosteroids in the induction of remission 
in patients with corticosteroid-resistant moderate to severe UC [261]. 
 
Inhibition of IL-12 and IL-23 
 
CD is associated with an enhanced Th1 cytokine response, which results in increased 
production of IL-12, a pro-inflammatory cytokine, that stimulates the production of IFN-γ and 
TNF-α. IL-12 is also involved in the differentiation of naïve T-cells into Th1 cells. It is a 
heterodimeric protein with 2 subunits: the p35 and p40. The structurally similar cytokine IL-
23 (its p40 subunit is identical to IL-12p40, and its p19 subunit shows certain similarities to 
IL-12 p35) has also an important role in intestinal inflammation, in conjunction with IL-6 and 
TGF-β1. IL-23 stimulates naïve CD4+ T cells to differentiate to Th17 cells. The highly 
aggressive immune response together with IL-12/IL-23 could have a determining role in 
initiation and perpetuation of chronic intestinal inflammation in CD [262, 263]. 
Recently p40 peptide-based vaccines have been developed. Pretreatment of rats with 
the vaccines induced specific antibodies to IL-12 and IL-23, which was associated with 
improvement of intestinal inflammation and fibrosis, indicating that the vaccine may provide 
a potential approach for the long-term treatment of CD [264]. 
A human study showed that treatment with a human monoclonal antibody against IL-
12 may induce clinical responses and remissions in patients with active CD. This treatment is 
associated with decreased Th1-mediated inflammatory cytokines at the site of disease [265]. 
Ustekinumab, and briakinumab are human monoclonal antibodies against IL-12 and 
IL-23, both targeting the p40 subunit. Ustekinumab significantly increased the rates of 
response and remission as maintenance therapy, and it may be particularly useful in patients 
who previously did not respond to anti-TNF therapy [266]. Briakinumab, however, in patients 
with moderate to severe CD was not effective for the induction or maintenance of remission 
([267]. 
Apilimod is an inhibitor of the transcription of IL-12 and IL-23. In a randomised 
controlled trial apilimod failed to induce significantly greater effect than placebo treatment 
[268]. 
 
Interferon-γ 
 
IFN-γ was found to be elevated in all genetic animal models of IBD and seems to have 
determining role in the development of Th1 responses. If the target of IBD therapy is to 
reduce Th1 responses, then inhibition of IFN-γ represents one potential therapeutic approach. 
Fontolizumab, a humanized monoclonal antibody to IFN-γ was shown to have a 
beneficial effect on disease activity [12, 211, 269]. An other study suggested that though a 
strong clinical response was not induced by fontolizumab, a significant decrease in C-reactive 
protein levels was observed. Further studies are necessary to determine its efficacy [270]. 
 
3.2.3. Inhibition of T-cell stimulation 
 
Since intestinal inflammation may be resulted by an increased activity of the effector 
T-cell population with excessive inflammatory responses and CD3 is required for T-cell 
activation, drugs that target T-cell activation may exert therapeutic effect in IBD. 
Visulizumab, a humanized anti-CD3 monoclonal antibody was demonstrated to induce 
apoptosis in activated T-cells selectively, and enhance the production of IL-10, a potent anti-
inflammatory cytokine [271]. It proved to be effective against T-cell transfer colitis [272]. 
The results of an open-label phase I human study with visilizumab in patients with severe 
corticosteroid-refractory UC suggested that it may be clinically beneficial [273]. 
Another study confirmed this beneficial effect of visulizumab in a pilot randomized 
phase I/II study. Visulizumab improved both symptomatic and clinical responses in severe, 
steroid-refractory UC, though, all patients experienced adverse reactions [274]. However, in a 
randomised, double-blind, placebo-controlled study visilizumab was not effective for severe, 
corticosteroid-refractory UC [275]. The same conclusion was drawn by Wood [276]. 
CD40 is also involved in T-cell activation. Humanized monoclonal antibody against 
CD40L has been developed, however in a phase II trial for CD due to side effect 
(thromboembolism) the trial was halted [277]. 
 
3.2.4. Inhibition of cell adhesion 
 
Lymphocyte trafficking to the gut is a basically important step in the initiation and 
maintenance of intestinal inflammation in patients with IBD. Alpha 4 integrin, a cell-surface 
glycoprotein involved in the adhesion, migration and activation of immune cells, is expressed 
on most of the lymphocytes, and combined with either a β1 subunit (that interacts 
predominantly with the endothelial ligands, vascular cellular adhesion molecule 1 /VCAM-1/) 
or a β7 subunit (that interacts predominantly with the mucosal addressin cellular adhesion 
molecule 1 (Mad-CAM-1)) [278]. The interaction between α4β7 integrin and Mad-CAM-1 is 
important in mediating leukocyte homing to gut mucosa [279]. Several therapeutic agents 
have been developed that specifically target the α4β7 subunit of integrin. 
Natalizumab, a humanized monoclonal antibody against the cell adhesion molecule 
α4-integrin subunit, was proved to be effective in experimental colitis both in the mouse and 
the rat [280, 281]. Moreover, the effect of natalizumab has been studied also in humans, and it 
was shown to block the adhesion and migration of white blood cells into the gut and to reduce 
chronic inflammation associated with CD [282]. Reviews based on relevant literature and 
meta-analysis of the controlled trials of natalizumab suggested that the therapy was superior 
to placebo in inducing remission of CD [283, 284]. However, natalizumab therapy is 
associated with an increased risk of reactivation of latent John Cunningham (JC) virus, which 
causes the potentially fatal progressive multifocal leukoencephalopathy (PML). The risk to 
develop PML is increased by the presence of anti-JC virus antibodies, and previous or 
concomitant treatment with immunosuppressive (IF-β1 or azathioprine) agents [285]. 
Vedolizumab (MNL-0002) is gut-specific, α4β7-integrin-neutralizing monoclonal 
antibody, that appears to lack systemic effects. It was particularly effective in UC and also in 
CD, indicating that vedolizumab might be therapeutic option for the treatment of therapy-
refractory patients [286]. A recent review evaluated the safety and efficacy of vedolizumab 
for the treatment of CD, and it was concluded that vedolizumab is an effective and well-
tolerated drug [287]. Though it does not increase the risk of infection, it was demonstrated 
that vedolizumab may reduce the number of Treg cells and consequently their suppressive 
effect on colonic inflammation (see review [288]). 
Alicaforsen (ISIS 2302) is an antisense oligodeoxynucleotide to ICAM-1 [289]. 
Experimentally, it inhibited the DSS-induced colitis both in mice and rats [289, 290], but in 
human studies both improvement of clinical symptoms and lack of effect have been shown in 
CD (see reviews [12, 211, 291, 292]). In patients with active UC alicaforsen enemas induced 
a beneficial effect, and the drug was well tolerated [291]. 
 
3.2.5. Immune stimulation 
 
Though granulocyte macrophage colony stimulating factor (GM-CSF) and 
granulocyte colony stimulating factor (G-CSF) are hematopoietic growth factors, they 
stimulate cells of the innate immune system (neutrophils, macrophages and DCs). They have 
also been shown to be produced within Paneth cells of intestinal mucosa, and their receptors 
are expressed within IECs [293]. Moreover, GM-CSF has been demonstrated to promote 
proliferation within these cells [294]. 
GM-CSF has been shown to reduce DSS-induced colitis and decrease the levels of 
pro-inflammatory cytokines (TNF-α and IL-1β) in colonic tissue samples [295, 296]. These 
results were confirmed recently; GM-CSF decreased the DSS-induced colitis and the 
expression of pro-inflammatory cytokines. In addition, the duration of ulcer healing was 
shorter and epithelial regeneration was facilitated in GM-CSF-treated mice [295]. Based on 
these preclinical results, a potential role for GM-CSF in the therapy of patients with IBD has 
been raised. 
Sargramostim (recombinant human GM-CSF) and filgrastim (recombinant human G- 
CSF) have been examined in several human studies and majority of them suggested a 
significant improvement and remission of CD ([297] and reviews [12, 298]). However, 
sargramostim in a phase III multicentre double-blind, placebo controlled study in patients 
with active CD failed to induce a significant difference in clinical efficacy compared to 
placebo. Further human studies are necessary to reveal their role in the treatment of IBD 
[211]. 
3.2.6. Anti-inflammatory cytokines 
IL-10 
 
IL-10 reduces the production of pro-inflammatory cytokines IL-1α, IL-6 and TNF-α, 
downregulates and controls the acute inflammation and thereby may improve the course of 
IBD. IL-10 polymorphisms have been shown to be associated with IBD and mutations in IL-
10 and IL-10 receptor (IL-10R) in patients with very early onset IBD was observed [299]. 
However, Buruiana et al. [300] on the basis of a systematic review of the literature 
concluded that IL-10 does not appear to provide any benefit for the treatment of active CD. 
 
IL-11 
 
IL-11 besides its thrombocytopoietic properties improves the mucosal barrier function 
and inhibits the inflammatory reaction by reducing expression of NF-κB and in turn IL-1, 
TNF-α and other proinflammatory peptides [301]. Therefore IL-11 was examined on 
experimental colitis in the rat induced by trinitrobenzene sulfonic acid (TNBS), where IL-11 
exerted protective effect [302]. Recent findings confirmed the beneficial action of IL-11: 
administration of exogenous IL-11 was found to be protective against lethal colitis in TLR2-
deficient mice (TLR2 is involved in maintaining epithelial barrier function) [303]. However, 
in a human study recombinant human IL-11 was less effective than prednisolone in the 
treatment of CD [304]. 
 
Interferon-β-1a (IFN-β-1a) 
Data of the literature reflect conflicting results on the effect of IFN-β-1a in IBD. Some 
studies indicate that IFN-β-1a exerts a therapeutic effect, while others found that IFN-β-1a did 
not produce a significant therapeutic action compared with placebo. Recent clinical trial in 
patients with CD came to the conclusion that there was no difference between the effects of 
the administration of IFN-β-1a and placebo [305, 306]. 
3.3. Restoration of barrier dysfunction and stimulation of mucosal healing and 
resistance 
 
Repeated intestinal epithelial damage and the consequent disruption of the intestinal 
barrier function is a key mechanism of IBD [3, 6]. Namely, the alteration of intestinal barrier 
function may result in translocation of commensal bacteria into the intestinal wall, leading to 
uncontrolled T-cell activation and inflammation. Damage of barrier integrity, with increased 
antigen and bacterial uptake is believed to be important in the pathophysiology of CD [4]. 
An intact barrier function of the intestinal epithelium prevents translocation of 
commensal bacteria into the mucosa. Consequently, though mucosal healing has been 
considered as a sign of complete healing of gut inflammation, it should be emphasized that 
mucosal healing can be considered as an initial step in suppression of inflammation [307]. In 
a systematic review Neurath and Travis [307] analyzed the influence of conventional 
therapeutic agents as well as the biologics on the healing of intestinal mucosal injury in IBD, 
and they concluded that while corticosteroids have little or no positive effects on 
induction/maintenance of mucosal healing in CD (but induced healing in patients with UC), 
azathioprine, in a lesser extent methotrexate, as well as natalizumab, infliximab, adalimumab 
and certolizumab pegol could induce mucosal healing [307]. 
Following injury of intestinal mucosa, IECs migrate into the damaged area to restore 
barrier integrity [298, 308], followed by proliferation of IECs to correct the epithelial defect. 
Finally, differentiation of IECs is necessary to restore mucosal barrier and epithelial function. 
These consecutive events (restitution, proliferation and differentiation) are mediated by 
regulatory proteins (such as chemokines), defensins, as well as by growth factors [298]. 
Growth factors have crucial role in cell restitution/proliferation/differentiation, and in 
angiogenesis. Moreover, TGF-β inhibits the differentiation of naïve T-cells to Th1/Th2 
subtypes. 
 
Growth hormone (GH) 
 
GH, a regulatory peptide that stimulates aminoacid and electrolyte uptake by the 
intestine, decreases intestinal permeability and stimulates collagen synthesis by induction of 
the expression of insulin-like growth factor (IGF). IGF was shown to promote epithelial repair 
in intestinal inflammation in preclinical animal models. For example, recombinant human 
growth hormone induced protective effects in TNBS-induced colitis [309]. A preliminary 
study showed that human growth factor was effective in CD, it improved the clinical 
symptoms (the number of liquid/soft stools, severity of abdominal pain and overall well 
being) and a statistically significant increase in circulating levels of IGF-1 was observed 
[310]. Further, placebo controlled human studies should be performed to determine the real 
place of growth factor in the therapy of IBD. 
 
Epidermal growth factor (EGF) 
 
Human recombinant EGF was shown to be effective in experimental colitis induced by 
TNBS given prophylactically, before the induction of colitis [311]. In UC patients EGF 
enemas administered parallel with mesalamine resulted in a significant improvement of 
symptoms [312], however, the effect of EGF enema alone (with placebo) has not been 
studied.  
 
Keratinocyte growth factor (KGF) 
 
KGF-1 and -2 are ligands of the fibroblast growth factor (FGF) family. KGFs may have 
role in wound healing and maintaining epithelial homeostasis. Expression of KGF-1 was 
found to be up-regulated in patients with active CD and UC, indicating that KGF may have 
role in the pathomechanism of IBD [313]. 
In animal models, KGF-2 proved to be protective against DSS-induced colitis given 
both prophylactically and therapeutically, both the clinical as well as the histological 
symptoms were improved significantly [314, 315]. However, human recombinant KGF-2 
failed to improve symptoms in patients with moderate to severe colitis, when compared with 
placebo. The contradictory results gained from animal experiments and human studies were 
explained by miscalculation in estimating the target dosage in humans [316]. However, a 
recent study confirmed the previous finding; KGF-2 (and EGF) did not show efficacy in 
phase II trials concerning patients with either CD or UC (see review [298]). 
 
Transforming growth factor β (TGF-β) 
 
The TGF-β superfamily in the intestinal epithelium controls cell proliferation, 
differentiation, apoptosis, as well as the activation state of differentiated cell types. The TGF-
β superfamily can further be divided into subfamilies and within the gut these include the 
TGF-β and bone morphogenetic protein (BMP) subfamilies. TGF-β superfamily ligands 
appear to facilitate the maintenance of normal epithelial homeostasis. Dysfunction of TGF-
β/BMP signaling within the intestinal epithelium has been raised to be involved in the 
pathogenesis of human colitis [317]. 
Recent preclinical studies demonstrated the role of BMP-7 both as a prophylactic and a 
therapeutic agent in experimental colitis induced by TNBS in the rat. Cytokine analysis of 
treated rats showed a reduced mRNA expression of pro-inflammatory cytokines, like IL-6, 
TNF-α, and ICAM-1 and decreased expression of pro-fibrogenic cytokines (TGF-β1) [318]. 
 
Vascular endothelial growth factor (VEGF) 
 
VEGF has basic role in the regulation of angiogenic processes during both development 
and in pathologic conditions (inflammation or tumorgenesis). Six mammalian VEGF family 
ligands (VEGF-A - VEGA-F) and 3 distinct receptors (VEGFR-1, VEGFR-2 and VEGFR-3) 
have been described. In rats, anti-VEGF antibody was investigated in colitis induced by 
iodoacetamide given intracolonically, and the results showed markedly less severe colitis as 
well as significant reductions in pro-inflammatory cytokines compared with controls. The 
beneficial effect of anti-VEGF antibody on colitis may be due to its moderating effects on 
vascular permeability and inflammatory cell recruitment [319]. Further studies showed that 
the levels of VEGF-A and VEGFR-2 were increased in patients with IBD as well as in DSS-
treated mice. Furthermore, overexpression of VEGF-A in mice worsened DSS-induced colitis, 
whereas administration of a soluble VEGF receptor led to decreased colonic inflammation 
[320]. Another angiogenic factor, placental growth factor (PIGF), has also been suggested to 
be a marker of pathologic angiogenesis and may play a critical role in pathogenesis of UC. 
Accordingly, inhibition of pathologic angiogenesis by either anti-VEGF or anti-PIGF, was 
demonstrated to be a new approach to attenuate UC [321, 322]. 
 
The role of additional growth factors, such as glucagon-like peptide or trefoil factors 
have been raised to be involved in healing and restoration of mucosal integrity in IBD [298, 
323]. Some of them have been studied in clinical trials or experimental colitis models and 
their potential role in the treatment of IBD remains to be further analyzed. 
However, it should keep in mind that both UC and CD are associated with dysplastic 
lesions and with increased risk of the development of colorectal cancer [324]. Since growth 
factors may induce stimulation of dysplastic tissues, growth factor therapy represents a 
potential risk for induction of malignant alterations in these patients [325]. 
In contrast, the recent results of Dube et al. [326] suggested that EGF receptors by 
modulating epithelial regeneration and reducing inflammation might limit the subsequent 
tumorgenesis. Namely, since chronic inflammation increases the risk of the development of 
cancer in IBD patients, disrupting the cycle of inflammation and epithelial injury may result 
in reduction of cancer risk. The authors showed that inactivation of the EGF-receptors 
accelerated the progression of colorectal tumors in mouse models of colitis, which suggests 
that therapy with EGF may reduce long-term cancer risk. 
 
3.4. Normalization of the altered composition of microbial flora 
 
Convincing evidence from both animal models and clinical observations indicate that 
the microbiota is the most probable factor that initiate chronic inflammation in CD. In 
accordance with this concept, antibiotics are one potential therapy in the treatment of active 
CD and UC. Moreover, it was shown that intestinal bacteria are necessary for the 
development of experimental colitis in the mouse [225, 327]. 
Bacterial adhesion and invasion into the intestinal mucosa may be particularly important 
in the development of intestinal mucosal inflammation, e.g., as in the case of Escherichia coli 
[328]. Though several pathogens have been supposed to be involved in the development of 
IBD (see section 2.3.), none of them have been proven to have a causal role, rather, microbial 
antigens that are present in the intestinal lumen under normal conditions seem to drive 
intestinal inflammation [213]. 
The microbiota is involved in both beneficial and deleterious processes in the intestinal 
tract. Epithelial cells may act as a mucosal protective and antimicrobial defensive system. 
Antimicrobial peptides, such as defensins, released by IECs and Paneth cells, play an essential 
role in host defense. Clinical studies showed reduced expression of both α- and β-defensins 
and the consequent reduced killing of certain microorganisms by the intestinal mucosa of 
patients with CD [329]. These findings indicate that defensin deficiency should be corrected 
in patients with CD. The nuclear receptor peroxisome proliferator-activated receptor gamma 
(PPAR-γ) plays an essential role in intestinal homeostasis. PPAR-γ was shown to function as 
an antimicrobial factor by maintaining constitutive epithelial expression of a subset of β-
defensin in the colon. Defective killing of several intestinal microbiota in colonic mucosa of 
PPAR-γ mutant animals, for example Candida albicans, Bacteroides fragilis, Enterococcus 
faecalis and Escherichia coli was demonstrated recently [330]. Furthermore, the PPAR-γ 
agonist rosiglitazone is a potent inducer of a subset of β-defensin in mouse colon. 
Accordingly, rosiglitazone was shown to be efficacious in mild-to-moderate UC [331]. This 
finding raises a new potential mechanism for the improvement of gut barrier function in CD. 
Enteric flora is altered in IBD patients. As intestinal bacteria are supposed to be 
involved in the pathogenesis of the disease, the therapeutic value of antibiotics in the 
treatment of IBD have been studied. Metronidazol, ciprofloxacin, rifamixin failed to induce a 
significant effect in UC, and also the results of clinical studies with metronidazole, 
ornidazole, ciprofloxacin, tobramycin, clarithromycin, co-trimoxazole and anti-mycobacterial 
agents in CD are conflicting and not convincing [7, 141, 142]. 
Since gastrointestinal microbiota has prominent role in driving inflammation in IBD, 
treatments that modulate the intestinal microbiota have been intensively analyzed. To 
counterbalance harmful bacteria, manipulation of the bacterial flora with probiotics (non-
pathogenic, beneficial bacteria) and prebiotics (dietary components that stimulate the growth 
of beneficial bacteria) is a potential alternative. Several mechanisms have been raised to be 
responsible for the potential beneficial effects of probiotics, such as production of bactericidal 
substances, competition with pathogens and toxins for adherence to the intestinal epithelium, 
enhancement of the innate immunity, modulation of pathogen-induced inflammation via TLR-
regulated signaling pathways and stimulation of intestinal epithelial cell survival and barrier 
functions (see review [332]). Results from experimental models of colitis suggest that TLR2, 
TLR4 and TLR9 are necessary for some probiotics to exert their anti-inflammatory effects in 
vivo [333]. However, in the light of literature probiotics show variable evidence for their 
efficacy [334, 335]. E.g. probiotics (Lactobacillus GG) were found to be ineffective in 
preventing recurrence after curative resection for CD [336]. Similarly, Mack [337] concluded 
in his review that there is little evidence and not enough convincing proof from trials for the 
effectiveness of probiotic in CD as well as in UC, though, clinical practice guidelines suggests 
their potential benefit in selected patients. 
Anderson et al. [338] recently published a review focusing on the efficacy of fecal 
microbiota transplantation (FMT). FMT was administered via colonoscopy/enema or via 
enteral tube. In patients treated for their IBD, the majority experienced a reduction of 
symptoms and disease remission. It was concluded, that though faecal microbiota 
transplantation may have been effective treatment of IBD, the evidence for the therapeutic 
effectiveness is limited and weak. Further randomized, controlled clinical studies are required 
to clarify the potential therapeutic value of FMT. 
As mentioned above, IBD is common in Western countries, where helminths are rare, 
and uncommon in less developed areas, which may be associated with poor sanitation and the 
concomitant helminth infections. Experimental data are in agreement with this assumption: it 
was shown that mice colonized with helminths are protected from the development of 
experimental colitis in various animal models (TNBS, DSS, IL-10 KO, T-cell transfer colitis) 
due to the activation of Treg cells and inhibition of effector T-cells [180]. Efficacy of 
helminths in CD and UC has been studied and the results suggest that Trichuris suis ova 
treatment was safe, and efficacious and may offer alternative therapeutic possibility for CD. 
Similar beneficial effect was observed in patients with UC (improvement: 47.3 % vs. 16.7 % 
placebo) [339, 340]. Recent experimental results showed a beneficial effect of the local 
treatment with Trichinella spiralis antigens in experimental colitis induced by dinitrobenzene 
sulfonic acid in mice, which suggest that helminth antigen-based therapy should be applied 
for IBD instead of infection with live parasites [341]. 
4. Conclusion 
 
The intensive research over the last decade has led to better understanding of the 
pathophysiology of IBDs. IBDs are initiated and perpetuated by an impaired immune 
response against the gut microbiota in genetically susceptible individuals. Predisposition to 
disease is determined by genes encoding immune responses which are triggered by several 
environmental influences. According to the present concept the disease is caused by a 
combination of factors, including genetics, immune dysregulation, barrier dysfunction, the 
change in microbial flora and environmental stimuli. The novel therapeutics, such as 
monoclonal antibodies, small molecule inhibitors, peptides, and vaccines target specific 
signaling and pathways involved in initiation, perpetuation and maintenance of intestinal 
inflammation. During the course of IBD several molecules were shown to be upregulated or 
downregulated in patients with IBD, which raised their potential target for drug development. 
However, in human studies many of the newly developed molecules failed to show significant 
biological action and had limited clinical efficacy. Moreover, antibody production to the 
therapeutic monoclonal antibodies may result in reduction of the efficacy of the biologics. 
Consequently, need for the development of additional strategies and targets is raised. 
Moreover, it also worth considering that combination of different factors may lead to the 
development of IBD. In addition, also the levels of cytokines potentially involved in 
pathophysiology of intestinal inflammation are different at the different stages of the disease; 
e.g. IFN-γ is significantly higher in early stage compared with late stage of IBD [342]. 
Consequently, more than one therapeutic option may be necessary during the course of the 
disease. The „step-up” therapeutic strategy represents partly this concept, however, there has 
been limited studies on the therapeutic efficacy of the combination of agents with different 
mechanism of action [12]. 
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Legends 
Fig. 1. Therapeutic approaches in IBD targeting different factors (genetic variations, immune 
dysregulation, barrier dysfunction and intestinal microbiota alterations), that are 
involved in the pathomechanism of IBD according to the recent consensus. 
 
 
 
